Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis
Journal
BMC cancer
Journal Volume
22
Journal Issue
1
Date Issued
2022-11-28
Abstract
The optimal duration of anti-PD-1 for cancer therapy has not been tested, especially when using combination therapy. Epidermal growth factor receptor (EGFR) pathway blocker was the top compound that enhanced T-cell killing of tumor cells in a high-throughput immune-oncology screen, possibly by stimulate the antigen presentation machinery and other mechanisms. We explored the effect of combination of EGFR inhibition with a short course of anti-PD-1 therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Subjects
Afatinib; Anti-PD-1; Head and neck squamous cell carcinoma; Immunotherapy; Pembrolizumab
SDGs
Type
journal article